Novel Cytotoxic Agents  by Morgensztern, Daniel & Belani, Chandra P.
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Daniel Morgensztern, MD,* and Chandra P. Belani, MD†
Cytotoxic agents continue to play an important role in thetreatment of cancer. Ongoing research studies involving
several cytotoxic agents were discussed at this meeting de-
spite the fact that the main focus of the symposium was on
molecularly targeted agents.
SUMMARY OF PRESENTATIONS
Picoplatin
Picoplatin is a new cisplatin analog designed to avoid
the development of platinum resistance. Preclinical studies in
human ovarian xenografts showed complete and durable
tumor regression with picoplatin, with continued remission
even after the cessation of treatment on day 28 at maximum
tolerated dose. In comparison, maximum tolerated doses of
cisplatin induced partial tumor regression during treatment
and rapid regrowth after cessation of treatment. In the same
model, picoplatin caused marked volume reduction in cispla-
tin-resistant tumor xenografts.
In a randomized multicenter study, 77 patients with
previously treated small cell lung cancer (SCLC) were treated
with picoplatin 150 mg/m2 intravenously every 3 weeks until
disease progression. The study population was subdivided
into chemotherapy refractory (failure to achieve response or
progressive disease during the first-line cisplatin-based che-
motherapy), resistant (initial response with relapse within 3
months from the last cycle of therapy), and sensitive (relapse
between 3 and 6 months after last cycle of therapy). Most
patients had refractory (44 patients) or resistant (27 patients)
disease, whereas only six patients had sensitive disease.
Response rates were observed in 9% of patients, and median
survival was nearly identical for refractory and sensitive
patients at 27 and 26 weeks, respectively. The most common
toxicity was myelosuppression and most notably, there were
no grade 3 to 4 nephrotoxicity, neurotoxicity, or ototoxicity.
The Study of Picoplatin Efficacy After Relapse is an ongoing
randomized phase III trial comparing overall survival for
picoplatin and best supportive care with best supportive care
alone in previously treated patients with SCLC.
Bendamustine
Bendamustine is a cytotoxic agent combining a purine-
like benzimidazol and a bifunctional alkylating nitrogen mus-
tard group. This agent, synthesized in the early 1960s, has
significant activity against hematological malignancies includ-
ing chronic lymphocytic leukemia, indolent non-Hodgkin lym-
phoma, and multiple myeloma, being approved in the United
States for the treatment of chronic lymphocytic leukemia and
indolent non-Hodgkin lymphoma in 2008. Several ongoing
trials are evaluating the efficacy of bendamustine in solid
tumors.1
Bendamustine was initially evaluated in two trials for
previously untreated patients with lung cancer. In the first
trial, 43 patients with lung cancer were treated with single
agent bendamustin 70 mg/m2 for 4 days every 4 weeks to a
maximum of six cycles. There were no responses among the
23 patients with non-small cell lung cancer (NSCLC),
whereas nine of 22 patients (40%) with SCLC achieved
partial response (PR). The treatment was very well tolerated,
with the main grade 3 toxicities consisting of nausea and
vomiting (7%), diarrhea (4.6%), leukopenia (4.6%), and
thrombocytopenia (4.6%). In the second study, 26 patients
with extensive disease SCLC received bendamustine 120
mg/m2 on days 1 and 2 every 3 weeks for a maximum of six
cycles. Among the 22 evaluable patients, complete response
(CR) was observed in two patients (9%), PR in eight patients
(36%), and stable disease (SD) in four patients (19%). Sur-
vival time was not reported, and there were no grade 3 or 4
toxicities. The same schedule of bendamustine (120 mg/m2
on days 1 and 2 every 3 weeks) was tested in 21 patients with
extensive disease-SCLC relapsing more than 2 months after
completion of first-line treatment. Response rate was 29%
with additional 29% achieving SD. Median time to progres-
sion, overall survival, and 1-year overall survival were 4
months, 7 months, and 16%, respectively. The main toxicity
was neutropenia, including three patients with grade 3, one
patient with grade 4, one patient with neutropenic fever, and
one treatment-related death due to sepsis. In a multicenter
German trial, 56 patients with SCLC were treated with a
combination of carboplatin area under the curve of 5 on day
1 and bendamustin 50 mg/m2 on days 1 and 2 every 3 weeks.
Among the 55 evaluable patients, the response rate was 73%
with 1 CR (1.8%) and 39 PR (71%). Main toxicities included
46% grade 3 to 4 leukopenia, 26% grade 3 to 4 thrombocy-
topenia, and 3.6% treatment-related deaths.
In summary, bendamustine seems to be a promising
agent worthy of further investigation in the treatment of
patients with SCLC. However, the role of bendamustine in
SCLC may be further defined in randomized phase III stud-
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ies. This drug seems to be only very limited activity in
patients with NSCLC.
Amrubicine
Amrubicine is a third-generation synthetic anthracy-
cline approved in Japan in 2002 for the treatment of both
SCLC and NSCLC. Its metabolite, amrubicinol, has 5 to 200
times higher growth inhibitory activity against tumor cell
lines compared with doxorubicin. The principal mechanism
of action seems to be through topoisomerase II inhibition.
Phase I studies determined the maximum tolerated dose of
130 mg/m2 in single dose schedule, 25 mg/m2 daily for 5
days, or 50 mg/m2 daily for 3 days. The dose-limiting toxicity
from earlier trials was myelosuppression with more than 80%
of patients developing neutropenia. Initial studies conducted
in Japan showed significant response rates for single agent
amrubicin in chemotherapynaive and previously treated
SCLC patients, including those with chemotherapy-refractory
disease.2
In a phase II US trial, 76 patients with chemotherapy-
sensitive SCLC patients previously treated with cisplatin-
based regimens underwent a 2:1 randomization to receive
topotecan 1.5 mg/m2 daily for 5 days (n  26) or amrubicin
40 mg/m2 daily for 3 days (n  50). The primary endpoint
was overall response rate. Response rates were significantly
higher for amrubicin compared with topotecan (34% versus
4%; p  0.004). Grade 3 to 4 toxicity for patients treated in
the amrubicin and topotecan arms were 67.3% and 78.3%,
respectively. In a phase II trial conducted in United States and
Europe, 75 patients with chemotherapy-refractory SCLC
were treated with amrubicin 40 mg/m2 daily for 3 days.
Overall response rate, the primary endpoint, was observed in
12 (17.4) of the patients, with 1.4% CR, 15.9% confirmed PR,
and 47.8% with unconfirmed PR or SD. Median progression-
free survival was 3.2 months, and overall survival data
remain immature. The most common grade 4 toxicities were
neutropenia (49.3%) and thrombocytopenia (21.7%). In a
phase I to II study involving the combination of cisplatin
(60–80 mg/m2 day 1) and amrubicin (40–45 mg/m2 days
1–3) every 3 weeks, response rate was 87.8% in the 44
patients enrolled into the recommended dose arm (cisplatin
60 mg/m2 and amrubicin 40 mg/m2), with median survival
time of 13.6 months, and 1-year survival of 56.1%. Main
toxicity was grade 4 neutropenia, occurring in 78% of patients.
In summary, amrubicin has promising activity in SCLC.
A phase III trial comparing amrubicin with topotecan (NCT
00547651) is ongoing to define the role of this agent in
patients with SCLC.
Trk Inhibitors
Tropomyosin-related kinases (TrKs) are a family of
receptor tyrosine kinases with three isoforms (TrKA, TrKB,
and TrKC) that are activated by neurotropins. Originally
isolated from neuronal tissues and though to be involved
mainly in the maintenance of neuronal cells, TrKs were later
found to play key roles in many cell types. TrK A and C
mutations are among the most commonly mutated genes in
lung adenocarcinoma and are associated with poor prognosis.
AZD6918 was the first oral inhibitor of TrKs, with
potent in vitro inhibition of TkK kinase and in vivo antitumor
growth in a neuroblastoma model. In the phase I trial, there
were unexpectedly low-plasma drug levels and highly vari-
able exposure reaching more than 10-fold differences among
the patients. Its development was discontinued in February
2009. CEP-7801 is a pan-TrK inhibitor that showed preclin-
ical activity in prostate cancer but no responses in nine patients
with hormone-refractory prostate cancer. PHA-848125 is an oral
inhibitor of TrKA and cyclin-dependent kinases 1, 2, and 4. It
demonstrated preclinical activity against lung, prostrate, and
pancreatic cancer models and is currently being evaluated in
a phase I study for patients with solid tumors.
In summary, TrKs remains a potential target, but the
first-generation compounds targeting this pathway have been
quite disappointing. Further studies should focus on com-
pounds with more favorable pharmacokinetics. In addition, as
with many other targeted agents, identification of specific
subgroups of patients most likely to benefit from the treat-
ment is crucial.
Pralatrexate
Pralatrexate is a member of the new class of rationally
designed antifolate medicines, with superior membrane trans-
port through the reduced folate carrier (RFC-1) and polyglu-
tamylation in tumor cells, resulting in increased intracellular
accumulation and enhanced cytotoxicity compared with
methotrexate. The phase I trial showed no significant hema-
tologic toxicity and the dose-limiting toxicity was stomatitis.
The maximum tolerated doses were 30 mg/m2 weekly or 170
mg/m2 every 2 weeks. In a phase II study involving 39
patients with previously treated advanced NSCLC, response
rate and median survival on pralatrexate were 10% and 13.5
months, respectively. The initial dose in this study of 150
mg/m2 every 2 weeks was decreased to 135 mg/m2 every 2
weeks in the last 10 patients due to stomatitis.3 The prala-
trexate-012 is a randomized phase IIb trial comparing prala-
trexate with erlotinib in previously treated patients with
advanced NSCLC. Never smokers are excluded, and the
patients are being stratified by cigarette smoking history
(15 pack-years versus 15 pack-years).
In summary, although TrKs remain a potential target,
results from the first-generation agents targeting this pathway
have been quite dissappointing. Because there is a suggestion
that RFC-1 expression may be associated with response to
pralatrexate, future studies may attempt to correlated out-
comes with RFC-1 expression in tumor samples in an attempt
to identify patients with higher probability of benefiting from
this treatment.
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